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Background: A detailed analysis of the expression of 440 cancer-related genes was performed after the combined
treatment of medulloblastoma cells with all-trans retinoic acid (ATRA) and inhibitors of lipoxygenases (LOX) and
cyclooxygenases (COX). The combinations of retinoids and celecoxib as a COX-2 inhibitor were reported to be
effective in some regimens of metronomic therapy of relapsed solid tumors with poor prognosis. Our previous
findings on neuroblastoma cells using expression profiling showed that LOX/COX inhibitors have the capability of
enhancing the differentiating action of ATRA. Presented study focused on the continuation of our previous work
to confirm the possibility of enhancing ATRA-induced cell differentiation in these cell lines via the application of
LOX/COX inhibitors. This study provides more detailed information concerning the mechanisms of the enhancement
of the ATRA-induced differentiation of medulloblastoma cells.
Methods: The Daoy and D283 Med medulloblastoma cell lines were chosen for this study. Caffeic acid (an inhibitor of
5-LOX) and celecoxib (an inhibitor on COX-2) were used in combined treatment with ATRA. The expression profiling
was performed using Human Cancer Oligo GEArray membranes, and the most promising results were verified using
RT-PCR.
Results: The expression profiling of the selected cancer-related genes clearly confirmed that the differentiating effects
of ATRA should be enhanced via its combined administration with caffeic acid or celecoxib. This effect was detected in
both cell lines. An increased expression of the genes that encoded the proteins participating in induced differentiation
and cytoskeleton remodeling was detected in both cell lines in a concentration-dependent manner. This effect was
also observed for the CDKN1A gene encoding the p21 protein, which is an important regulator of the cell cycle, and for
the genes encoding proteins that are associated with proteasome activity. Furthermore, our results showed that D283
Med cells are significantly more sensitive to treatment with ATRA alone than Daoy cells.
Conclusions: The obtained results on medulloblastoma cell lines are in accordance with our previous findings on
neuroblastoma cells and confirm our hypothesis concerning the common mechanism of the enhancement of
ATRA-induced cell differentiation in various types of pediatric solid tumors.
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Medulloblastoma (MBL), an embryonal neuroectodermal
tumor of the cerebellum, is the most common type of ma-
lignant brain tumor in children. Although recent advances
in MBL therapy have led to a dramatic increase in survival
rate, the mortality rate is currently approximately 20–40%
[1]. Moreover, MBL survivors are often affected by treat-
ment-related side effects such as growth hormone deficiency,
gonadal alterations, hypo- or hyperthyroidism, and long-
term cognitive, neuropsychological and academic impair-
ments, etc. New approaches are thus needed to improve
the survival rate and to reduce the negative side effects of
MBL treatment [2].
The induced differentiation of tumor cells has become
a promising strategy in modern antineoplastic therapy.
Retinoids, which are derivatives of vitamin A, are the most
frequently used group of cell differentiation inducers. The
regulation of relevant cell signaling pathways via retinoids
is based on the activation of two groups of nuclear recep-
tors, RAR and RXR [3,4]. These activated receptors can
influence the transcription either directly by binding to
the DNA or indirectly by interacting with other transcrip-
tion factors [5,6].
In general, retinoids play an important role in cell
proliferation and differentiation, and their efficacy in
the treatment of various types of tumor cells has been
described both in vivo and in vitro [7-11]. However, the
toxicity of and intrinsic or acquired resistance to retinoids
substantially limit their use in clinical protocols [12].
Therefore, special attention has been paid to treating
cancer cells with a combination of retinoids and other
compounds that may enhance or prolong their antineo-
plastic effects. The enhancing effects of these modulators
were described in several clinical trials focused on the
treatment of leukemia [13-16]; they were also demon-
strated under in vitro conditions using tumor cells of a
neurogenic origin [17-20].
To date, many studies on various cancer cell lines have
reported the additive or synergistic effects of combined
treatment with retinoids and inhibitors of lipoxygenases
(LOX) [21-24] or cyclooxygenases (COX) [25-27]. The
molecular mechanisms of this modulation remain un-
known, but the published data suggest the inhibition of
the retinoid degradation pathways [28] or the cooperation
of compounds that are utilized in cell signaling inhibition
(through the PI3K/Akt pathway) or the induction of the
mitochondrial apoptotic pathway [25].
Our previous studies were also focused on how to
enhance the differentiation effect of all-trans retinoic
acid (ATRA) through its combination with LOX/COX
inhibitors in neuroblastoma cell lines [20,29]. In these
experiments, we used caffeic acid (CA) as an inhibitor
of 5-LOX and celecoxib (CX) as an inhibitor of COX-2.
Our results clearly confirmed that the ATRA-induceddifferentiation of neuroblastoma cells can be enhanced
via the combined application of these inhibitors [20,29].
Furthermore, data from the expression profiling of the
treated cells showed an increase in the expression of the
genes involved in the process of retinoid-induced neuronal
differentiation, especially in cytoskeleton remodeling after
combined treatment [20].
To verify these findings, we used a different type of
neurogenic tumor cells, i.e. established medulloblastoma
cell lines but the same experimental design for the treat-
ment of these cells. Our new data from the gene expression
profiling of medulloblastoma cells also demonstrated the
capability of CA or CX to enhance the cell differentiation
induced via ATRA.
Methods
Cell lines and cell culture
Daoy (ATCC HTB-186™) and D283 Med (ATCC HTB-185™)
medulloblastoma cell lines were used in this study. These
cell lines were chosen according their different origin
(primary tumor vs. metastatic site) and their different
biological features as described by supplier in the docu-
mentation to cover known heterogeneity in this disease.
Both of these cell lines are widely used in medulloblastoma
research. These cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F-12 medium
mixture (1:1) supplemented with 20% fetal calf serum, 1%
non-essential amino acids, 2 mM L-glutamine, 100 IU.ml−1
penicillin, and 100 mg.ml−1 streptomycin (all purchased
from PAA Laboratories, Linz, Austria). Cell culture was
performed under standard conditions at 37°C in a humidi-
fied atmosphere containing 5% CO2. Both of these cell
lines were subcultured 1–2 times weekly. The Research
Ethics Committee of the University Hospital Brno approved
the study protocol.
Chemicals
ATRA (Sigma-Aldrich, St. Louis, MO, USA), CA (Sigma),
and CX (LKT Laboratories, St. Paul, MN, USA) were pre-
pared as stock solutions at concentrations of 100 mM in
dimethyl sulfoxide (DMSO) (Sigma). For experiments,
these stock solutions were diluted in fresh cell culture
medium to obtain final concentrations as follow: 0.05 and
0.1 μM of ATRA for the treatment of D283 Med cells, 1
and 10 μM of ATRA for the treatment of Daoy cells, 13
and 52 μM of CA, as well as 10 and 50 μM of CX for the
treatment of both cell lines.
Experimental design
The experimental design was the same as that in our
previous studies [20,29]: the cell populations were treated
with ATRA alone or with ATRA and an inhibitor (CA or
CX) at the concentrations mentioned above. The concen-
trations of ATRA and inhibitors were chosen on the basis
Table 1 Sequences of primers used for RT-PCR
Gene Primer sequence Product
CDKN1A F: 5′ TTA GCA GCG GAA CAA GGA GT 3′ 225 bp
R: 5′ GCC GAG AGA AAA CAG TCC AG 3′
GDF15 F: 5′ CTC CAG ATT CCG AGA GTT GC 3′ 169 bp
R: 5′ AGA GAT ACG CAG GTG CAG GT 3′
HSP90AB1 F: 5′ CGC ATG AAG GAG ACA CAG AA 3′ 169 bp
R: 5′ TCC CAT CAA ATT CCT TGA GC 3′
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the plasma levels obtained using these compounds
therapeutically [23,30-33]. However, lower concentra-
tions of 0.05 and 0.1 μM ATRA were used for treating
the D283 Med cells due to the predominant cytotoxic
effect on the cell populations at higher concentrations
[34]. In all experiments, the cells were seeded into Petri
dishes or culture flasks 24 h prior to the treatment. Un-
treated cells were used as controls in all experiments.
Expression profiling
The total RNA of the treated cell populations was isolated
using the GenElute™ Mammalian Total RNA Miniprep
Kit (Sigma), and its concentration and integrity were
determined using a spectrophotometer. This isolation
of RNA was performed at day 3 after treatment. The
conversion of the experimental RNA into cDNA and its fur-
ther transcription and biotin-UTP labeling was performed
using TrueLabeling-AMP™ 2.0 cRNA (SABiosciences,
Frederick, MD, USA). After purification with the Super-
Array ArrayGrade cRNA Cleanup Kit, the labeled target
cRNA was hybridized to Human Cancer OHS-802 Oligo
GEArray membranes that profile 440 genes (both SABios-
ciences). The expression levels of each gene were detected
via chemiluminescence using the alkaline phosphatase-
conjugated streptavidin substrate. The membranes were
then recorded using the MultiImage™ II Light Cabinet
DE- 500 (Alpha Innotech, CA, USA). The image data were
processed and analyzed using the GEArray Expression
Analysis Suite software (SABiosciences) with background
subtraction. All data were standardized as a ratio of the
gene expression intensity to the mean expression intensity
of the selected HSP90AB1 housekeeping gene, which was
chosen using the GeNorm [35] and NormFinder [36]
software tools. Standardized spot intensity ratios (treated/
control samples) were calculated and data filtering criteria
were as follows: genes with ratio higher than 2 were rated
as upregulated and genes with ratio lower than 0.5 were
rated as downregulated. The expression of the specific
gene was evaluated as changed if the same trend of
change, i.e. upregulation or downregulation was detected
at least in four experimental variants (of six in total) re-
gardless the concentrations used for treatment. Cluster
analyses were performed using the GEArray Expression
Analysis Suite software according to the design of the ex-
periments, i.e., separately for each cell line and inhibitor
type. DAVID software tool [37] was used for primary de-
tection of relevant pathways.
RT-PCR
The changes in the expression of the two selected candidate
genes were evaluated using RT-PCR. The RNA was isolated
as described above. A total of 0.25 μg RNA was then
reverse transcribed using M-MLV reverse transcriptase(Top-Bio, Prague, Czech Republic) according to the
manufacturer’s protocol. RT-PCR was performed on
4 μl cDNA using Taq DNA polymerase 1.1 (Top-Bio)
with human primers for the CDKN1A and GDF15 candi-
date genes as well as the HSP90AB1 housekeeping gene
(Table 1) in 20 μl of the reaction volume. The PCR reac-
tion was performed with denaturation at 94°C for 4 min,
annealing at 60°C for 30 s, and elongation at 72°C for
1 min (35 cycles for all primers) (Table 1). A total of 10 μl
of the PCR product was loaded on the 1% agarose gel and
examined using electrophoresis. The optical density was
stained and quantified using ImageJ software [38], and the
data were normalized to HSP90AB1 expression.
Results
The present study was focused on a detailed analysis of
Daoy and D283 Med medulloblastoma cells after the
combined application of ATRA and LOX/COX inhibitors.
CA as the specific inhibitor of 5-LOX and CX as the spe-
cific inhibitor of COX-2 were used in these experiments.
The changes in the expression of cancer-related genes
were evaluated using expression profiling. Furthermore, a
detailed analysis of the expression of five candidate genes
was performed using RT-PCR to verify the microarray
results. We used the same experimental design as our
previous studies on neuroblastoma cells [20,29].
In Daoy cells, changes in the expression of 80 cancer-
related genes were detected after combined treatment
with ATRA and inhibitors (Figure 1A). A total of 29 of
these genes demonstrated changed expressions after
combinations of ATRA and CA as well as of ATRA and
CX. The expressions of another 29 genes were changed
only after the combined treatment of ATRA and CA. A
total of 22 different genes showed changes in expression
after undergoing combined treatment with ATRA and
CX (Figure 1A).
In D283 Med cells, the expressions of 37 genes were
changed (Figure 1B). Of these, 22 showed changes after
combined treatment with ATRA and CA as well as with
ATRA and CX. Changes in the expression of another 11
genes were identified after treatment with ATRA and
CA only. Similarly, the expressions of 4 different genes
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Figure 1 Summary of detected changes in the expression of 440 cancer-related genes after the combined treatment of the Daoy (A)
and D283 Med (B) cell lines. The black circles indicate the total number of genes with changed expression after combinations of ATRA with CA
or CX. The green areas indicate the number of genes with changed expression after combined treatment with ATRA and CA only. Similarly, the
violet areas indicate the number of genes with changed expression after combined treatment with ATRA and CA only. The gray overlays indicate
the number of genes that demonstrated changed expressions after treatment with ATRA in both combinations; i.e., with CA as well as with CX.
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after cluster analysis, which grouped the genes or gene
groups by the type of changes in their expressions
(Figure 2). Based on this analysis, three typical patterns of
changes in gene expression are described:
(i.)Genes with strong concentration-dependent changes
in their expressions. This pattern was typical in the
I.A, II.A, III.A, and IV.A groups, in which the upreg-
ulation of gene expression was detected. This
concentration-dependent pattern was also detected
in the groups with downregulated gene expressions,
i.e., in the I.E., II.D, III.D, and IV.C groups.
(ii.)Genes for which the expression was upregulated
(groups I.B and II.C) or downregulated (group III.C)
after treatment with lower concentrations of
reagents. The use of higher concentrations had no
or minimal influence on the expression of these
genes.
(iii.) Genes with changes in their expressions after
treatment with higher concentrations of reagents
only. This pattern was characteristic in the II.B and
III.B groups; however, such trends were also obvious
in the I.A and IV.A groups.
Similarities in the gene expression changes are sum-
marized in Table 2 and Table 3. The genes with changed
expression in a particular cell line after combined treat-
ment with ATRA and both inhibitors (CA or CX) are given:
8 genes were upregulated and 8 genes were downregulated
in the Daoy cells; 16 genes were upregulated and 3 were
downregulated in the D283 Med cells (Table 2). Two of
these genes, GDF15 and UBE2L6, were upregulated in
both cell lines after all types of combined treatment
(Table 2). Changes in gene expression after the same type
of combined treatment (ATRA with CA or ATRA with
CX) were identified in both cell lines; 2 of the genes were
upregulated and 1 was downregulated after treatment with
ATRA and CA, while 8 were upregulated and 1 wasdownregulated after treatment with ATRA and CX
(Table 3).
The analysis of the detected changes in gene expressions
showed a concentration-dependent increase in the expres-
sion of genes known to be involved in the process of
retinoid-induced differentiation and especially of the genes
generally associated with the regulation of the cell cycle,
of genes involved in mitochondrial metabolism, etc. The
observed changes in the expressions of two selected candi-
date genes - GDF15 (Figure 3) and CDKN1A (Figure 4) -
were subsequently verified via RT-PCR.
Discussion
At present, retinoids (powerful inducers of cell differen-
tiation) have become a part of many therapeutic regi-
mens in pediatric oncology, especially in the treatment
of solid tumors of neurogenic origin [39-43]. In our pre-
vious experiments, we demonstrated the enhancement
of the ATRA-induced differentiation of neuroblastoma
cells via the combined application of LOX/COX inhibi-
tors [20,29].
In our present study, we profiled the expression of 440
cancer-related genes in medulloblastoma cells after the
same type of combined treatment (see above). Our results
clearly confirmed our previous finding that ATRA-induced
cell differentiation is enhanced via combined treatment
with CA (inhibitor of 5-LOX) or with CX (inhibitor of
COX-2) because the expression of the genes involved in
the process of induced differentiation is increased in a
concentration-dependent manner. A comparison of two
established medulloblastoma cell lines showed a higher
sensitivity in Daoy cells (compared with D283 Med cells)
to the combined treatment with ATRA and inhibitors;
nevertheless, our pilot experiments indicated that D283
Med cells were apparently more sensitive to the ATRA
alone [34,44]. The same difference in sensitivity of Daoy
and D283 Med cell lines to the ATRA was already de-
scribed and the higher sensitivity of D283 Med cells is
explained by expression of OTX2, a transcription factor,
Figure 2 Results of gene cluster analysis after the expression profiling of treated cells. The genes were clustered according to the type of
changes in the expression in the respective cell line (Daoy or D283 Med) after the combined treatment with ATRA and inhibitors (CA or CX). The
cells were treated with ATRA alone or in combination with CA (an inhibitor of 5-LOX) or CX (an inhibitor of COX-2); numbers indicate the concentration
in μM. The green color at the farthest left end of the color scale corresponds to the minimal value; the red color at the farthest right end of the color
scale corresponds to the maximal value; the black color in the middle corresponds to the average value. Each of the other values corresponds to a
certain color according to its magnitude. The colors are assigned according to the value of the particular gene expression in all samples in the
respective experimental variant (I, II, III or IV). Genes discussed in the text in detail are highlighted by red dots.
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Table 2 Genes with changed expression in a particular
cell line (Daoy or D283 Med) after combined treatment
with ATRA and both inhibitors (CA or CX)
Daoy cell line
Upregulated: ACP2, GDF15, HLA-G, KRT18, MARS,
NOTCH2, PPARG, UBE2L6
Downregulated: CD24, COL6A3, FBN1, GAS6, HMGB1,
JUND, PLK2, YBX1
D283 Med cell line
Upregulated: AP2M1, ATF4, BLMH, CANX, CDKN1A,
COX6C, COX7A2, FTL, GDF15, MAP2K2,
PFDN5, PPARD, RARA, RHOA, SOD1,
TIMP1, UBE2L6, UCHL1
Downregulated: KPNA2, MYBL2, MYC
The genes that were influenced via the combinations of both inhibitors are
typed in bold.
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entiation in medulloblastoma cells [45].
The three patterns of changes in gene expression de-
scribed here were very similar to our previous results on
neuroblastoma cells [20]. In terms of the individual genes,
we noted significant changes in the expression of the
GDF15, RHOA, and RHOC genes. Although the expres-
sion of the GDF15 gene was enhanced in both cell lines
via combined treatment with ATRA and both inhibitors
(Figures 2 and 3), changes in the expression of the RHOA
and RHOC genes were detected in the D283 Med cells
only (Figure 2). These two genes are members of the Rho
GTPases family and are known to participate in cyto-
skeleton rearrangement and regulation processes such
as changes in cell morphology during cell differentiation,
proliferation and motility [46,47]. This finding is in ac-
cordance with our pilot study in which the decrease in
proliferation activity and in the formation of multicellular
aggregates was reported after the combined treatment
(using CA or CX) of D283 Med cells [44].
The protein encoded by the GDF15 gene is an important
regulator of cell differentiation during embryonal develop-
ment, especially in neural tissues [48]. This protein also has
other important functions in the regulation of immuneTable 3 Genes with changed expression detected after
the same type of combined treatment (ATRA with CA or





Upregulated: ATF4, CDKN1A, GDF15, HMGA1, HMGB1,
PFDN5, TIMP1, UBE2L6
Downregulated: AP2M1
The genes that were influenced via the combinations of both inhibitors are
typed in bold.response or response to stress factors [49], and some
studies have described its role as a paracrine mediator
in the p53 cell signaling pathway that can inhibit cell
proliferation and induce apoptosis [50,51]. Furthermore,
the expression of GDF15 correlated with the amount of
the p21 protein that was encoded by the CDKN1A gene
[50,51]. Although the overexpression of GDF15 was
detected in both cell lines after combined treatment
with both inhibitors (Tables 2 and 3), we observed some
differences between these cell lines. The expression of
GDF15 increased in Daoy cells in a concentration-
dependent manner (Figures 2 and 3A), but the changes in
GDF15 expression in D283 Med cells were not so obvious
(Figures 2 and 3B).
As mentioned above, some previous studies have dem-
onstrated a correlation between the expressions of the
GDF15 and CDKN1A genes [50,51]. The CDKN1A gene
encodes the p21 protein, which serves as an important
regulator of the cell cycle progression via the inhibition
of cyclin-dependent kinases. In our experiments, the
expression of CDKN1A was enhanced in both cell lines
after combined treatment with ATRA and CX, whereas
the combination of ATRA and CA did not show a similar
effect (Table 3, Figure 4). The increase in CDKN1A ex-
pression after treatment with retinoids was described
in many human malignancies under in vivo and in vitro
conditions: acute promyelocytic leukemia [52], acute
T-lymphoblastic leukemia [53], pre-B lymphoma [54],
hepatoblastoma [55,56], and neuroblastoma [57-60]. Our
in vitro data confirmed these findings (especially in D283
Med cells) and also clearly showed that this effect of
ATRA can be enhanced through its combined administra-
tion with CX (Figure 4B).
Furthermore, we detected the upregulated expression
of the UBE2L6 gene, which encodes a member of the E2
ubiquitin-conjugating enzyme family in both cell lines
after combined treatment with both inhibitors (Tables 2
and 3). The overexpression of the ACP2 gene encoding a
beta-subunit of lysosomal acid phosphatase was observed
in Daoy cells after combined treatment with both inhibi-
tors (Table 2). The upregulated expression of both of these
genes indicated an increased activity of proteasome in the
treated cells. Higher proteasome activity was reported in
breast carcinoma cells [61] as well as in acute promyelocy-
tic leukemia cells [62,63] after treatment with retinoids.
However, the relationship between retinoids and prote-
asome activity should be associated with resistance to
retinoids [64]. This mechanism of resistance to reti-
noids, i.e., the increased activity of proteasome in Daoy
cells, could be one of the possible explanations for the
differing sensitivity demonstrated by these cell lines to
ATRA treatment, as reported in our pilot study [44]. This
hypothesis is also supported by the fact that the upregula-
tion of the UCHL1 gene encoding a deubiquitinating
Figure 3 Changes in the expression of the GDF15 gene in Daoy (A) and D283 Med (B) cells analyzed using RT-PCR. The cells were
treated with ATRA alone or in combination with CA (an inhibitor of 5-LOX) or CX (an inhibitor of COX-2); numbers indicate the concentrations of
these compounds in μM. Respective numerical data from densitometry for three independent experiments are shown in the graphs: X-axis,
treatment condition; Y-axis, relative gene expression. The data represent the means ± SD; they were normalized to the expression of the HSP90AB1
housekeeping gene and were related to the untreated control cells. Representative electrophoresis is presented for each cell line.
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after combined treatment with both inhibitors (Table 2).
Moreover, the protein encoded by this gene was found
solely in mature neurons [65]; its increased expression in
D283 Med, which is apparently enhanced via a combined
treatment with ATRA and inhibitors, should indicate the
neuronal differentiation of D283 Med after experimental
treatment.
Higher sensitivity of D283 Med cells to the ATRA-
induced neuronal differentiation is also indicated by the
overexpression of two genes encoding subunits of cyto-
chrome C oxidase, COX6C and COX7A2, after both types
of combined treatment (Table 2). An increased mitochon-
drial activity after treatment with retinoids was reported
in neuroblastoma cell lines [66], and it was demonstrated
that more differentiated neuronal cells exhibit higherFigure 4 Changes in the expression of the CDKN1A gene in Daoy (A)
treated with ATRA alone or in combination with CA (an inhibitor of 5-LOX)
these compounds in μM. Respective numerical data from densitometry for
treatment condition; Y-axis, relative gene expression. The data represent th
housekeeping gene and were related to the untreated control cells. Represoxygen consumption rates as well as metabolic rates [67].
These findings thus support the presumed neuronal differ-
entiation of D283 Med cells treated with ATRA and the
capability of CA and CX to enhance this effect. Further-
more, a similar upregulation of these two genes was previ-
ously detected in neuroblastoma cell lines after the same
type of experimental treatment [20].
The presented results are closely connected to our
previously published studies reporting encouraging treat-
ment responses to metronomic therapy in children suffer-
ing from some types of relapsed solid tumors with poor
prognosis [42,43,68]. In these protocols, retinoids are
administered in combination with celecoxib (as an
anti-angiogenic agent) and several cytotoxic agents.
The usefulness of this type of metronomic therapy was
also demonstrated in patients with MBL [43,69,70]. Inand D283 Med (B) cells analyzed using RT-PCR. The cells were
or CX (an inhibitor of COX-2); numbers indicate the concentrations of
three independent experiments are shown in the graphs: X-axis,
e means ± SD; they were normalized to the expression of the HSP90AB1
entative electrophoresis is presented for each cell line.
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that the combined administration of retinoids and cele-
coxib should also be beneficial in enhancing tumor cell
differentiation. Furthermore, a very similar effect could be
achieved through the dietary uptake of plant phenolic
compounds including caffeic acid [71,72].
Conclusion
To summarize, our results on two established medullo-
blastoma cell lines – Daoy and D283 Med – confirmed
our previous findings in leukemia and neuroblastoma
cells that the differentiating effects of ATRA should be
enhanced in its combined administration with caffeic
acid (an inhibitor of 5-LOX) or celecoxib (an inhibitor
of COX-2). This effect was apparently achieved in both
cell lines via the increased expression of genes encoding
proteins participating in inducing the differentiation and
cytoskeleton remodeling (GDF-15, Rho GTPases) or the
p21 protein, which is an important regulator of the cell
cycle and of proteins associated with proteasome activity.
Furthermore, our results showed an important difference
between the established MBL cell lines: the Daoy cells
showed the same sensitivity as the cell lines that were
derived from other types of pediatric solid tumors, but
the D283 Med cells were significantly more sensitive to
the treatment with ATRA alone (this effect was further
enhanced via combined treatment with LOX/COX inhibi-
tors). To clarify detailed mechanisms of such difference,
additional experiments concerning more cell lines derived
from various MBL subtypes are needed. Nevertheless, the
obtained results confirmed our initial hypothesis regarding
the common mechanism of enhancement in ATRA-
induced cell differentiation in various types of pediatric
solid tumors.
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